Biotech Values

[mcbio]

Supergen - Thoughts on PIM Kinase Inhibitor and Stock In General

Supergen claims that its drug, SGI-1776, which is about to enter Phase I, is the first PIM kinase inhibitor in clincal trials. The drug targets cancer. Does anyone know if that is in fact true and how does a PIM kinase inhibitor compare and stack up to a tyrosine kinase inhibitor? If this truly is the first, you would think this would draw some interest down the road wouldn't you?

Any other thoughts on the rest of their pipeline or the market cap (around $100 million)? They've already got Dacogen on the market, which generates revenue to finance the pipeline.